IntroductIon
Gene therapy approaches are of increasing interest, and >1,700 clinical trials have already been approved worldwide. 1 Since the discovery that plasmid DNA injection can be an efficient way to express a specific protein in vivo, 2 the so-called "nonviral" gene therapy field has been growing. The production of plasmid DNA requires specific markers able to select plasmid-containing strain after bacterial transformation and during the amplification process. When plasmids are passed on to the daughter cells, the system is segregationally stable only if each daughter cell contains at least one copy of the plasmids. 3 Plasmid stability should be correlated with the number of copies of the plasmid in the parent bacteria: high-copy plasmids such as the pUC vectors which are maintained at several hundred copies per cell should be highly stable because the occurrence of plasmid-free daughter cells is statistically improbable. However such plasmids are lost at an alarming high rate under nonselective conditions. 4 Indeed, plasmid imposes an additional metabolic load for the bacteria which strongly influence its growth rate and plasmid-free cells that enjoy a nontrivial advantage and can overgrow the whole population (for review, 3, 4 ). Therefore, it is essential to impose a selection pressure favorable to the selection of bacteria containing the plasmid of interest. Genes conferring resistance to antibiotics are often used as plasmid selection markers and require growing the bacteria in an antibiotic-containing culture medium. However, this approach raises several safety concerns that should be carefully considered.
These considerations have not escaped the attention of regulatory authorities. The European Pharmacopoeia 7.0 states, "Unless otherwise justified and authorised, antibiotic-resistance genes used as selectable genetic markers, particularly for clinically useful antibiotics, are not included in the vector construct. Other selection techniques for the recombinant plasmid are preferred". 5 World Health Organization (WHO) guidelines demand that "the possibility of expression of such gene sequences in mammalian cells or in micro-organisms which are potentially pathogenic, and the possible clinical consequences of such expression, should be considered". 6 In the same way, the European Agency for the Evaluation of Medicinal Products (EMA) specifies that "consideration should be given to avoiding their use, where feasible". It states also that "special attention should be given to the nature of the selection marker. The use of certain selection markers, such as resistance to antibiotics, which may adversely impact on other clinical therapies in the target population, should be avoided" and that "it is undesirable to use in production, agents which are known to provoke sensitivity in certain individuals, for example, β-lactam antibiotics". 7 Finally, US Food
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and Drug Administration recommends that "penicillin and other β-lactam antibiotics be avoided during production, due to the risk of serious hypersensitivity reactions in patients. If antibiotic selection is used during production, it is preferable not to use selection markers which confer resistance to antibiotics in significant clinical use, in order to avoid unnecessary risk of spread of antibiotic resistance traits to environmental microbes. Also, residual antibiotic in the final product should be quantitated when possible, and the potential for allergy considered". 8 These concerns are of special importance when considering vaccination, where a very large population is treated in a preventive manner, and plasmid-based genetic vaccination represents the actual major development axis for plasmids as a therapeutic agent.
It is timely to consider innovative approaches concerning bacteria selection during plasmid production. This article reviews the existing strategies for plasmid maintenance and, in particular, those that do not require the use of antibiotic resistance genes. Minicircle strategy that involves removing of the antibiotic resistance gene from the initial vector will also be discussed. Furthermore, reported use of antibiotic-free plasmids for preclinical or clinical studies will be discussed. These antibiotic-free approaches will certainly know a growing success in the next few years because of their improved safety profiles.
AntIbIotIc reSIStAnce GeneS
Over the last century, antibiotics became a main treatment to fight bacterial infections. However, bugs have developed their own shield, and antibiotic resistances compromise the efficacy of current therapies. Emergence and spreading of bacteria resistant to high doses of antibiotics have been favored by their overuse and misuse, and there is now evidence of increasing number of multiple-drug resistant organisms (for review 9, 10 ). Bacteria can acquire resistance to antibiotics by either genetic mutation or by horizontal gene transfer (accepting resistance genes from other bacteria).
Several antibiotic resistance genes have been widely used as selectable markers in routine biotechnology. The bla gene encodes a β-lactamase that confers resistance to ampicillin which is commonly known as a broad-spectrum antibiotic. The use of this resistance gene as a selection marker is not currently acceptable for clinical trial because of the risk of spreading in the environment and because of potential horizontal gene transfers which could provide pathogenic bacteria with resistance to antibiotics that are used for patient treatment. The nptII gene appears to be a more appropriate selection marker as it confers resistance to kanamycin that is not so commonly used to treat human infections because of its numerous side effects.
Another concern about the use of antibiotic resistance genes for selection is that bacterial cultures require a large amount of antibiotics which are expensive compounds. It is difficult to avoid their degradation or inactivation, and antibiotics may not be completely effective, in particular in continuous culture conditions limiting the scale-up. Moreover, residues of antibiotics could contaminate the final product even after purification. This could be particularly problematic for patients with hypersensitivity which is relatively common for β-lactam antibiotics.
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It is also important to note that the synthesis of antibiotic resistance proteins recruits part of the available metabolic resources in bacteria. Moreover, markers are usually produced at levels far exceeding those that are necessary for plasmid maintenance and selection. The metabolic energy consumed to synthesize these enzymatic markers cannot be devoted to plasmid production, and this metabolic burden has thus an impact on culture performance and on plasmid yield. 12, 13 Also, antibiotic resistance genes are large prokaryotic genes, which induce two drawbacks: (i) they increase plasmid size, which induces a decrease in transfection efficiency, and (ii) they bear unmethylated CpG sequences specific to prokaryotic backbones, which induce the innate immune system. The effect of plasmid size on gene transfer efficiency has been studied in vitro and in vivo. To achieve transfection, a plasmid has to find its way to the nucleus through the relatively viscous cytosolic environment. The nuclear pore by itself is also considered as a strong barrier for plasmid diffusion to the nucleus. 14, 15 For both these reasons, it might be assumed that smaller size plasmids might reach more efficiently the cell nucleus during any transfection procedures, whether mediated by a chemical vector or through a physical delivery method such as electrotransfer. Indeed, it has been shown that smaller plasmids bearing the same expression cassette as larger ones were more efficiently expressed after in vivo gene transfer and that the increase in gene transfer efficiency was inversely correlated to plasmid size both in vitro and in vivo. [16] [17] [18] Antibiotic-free plasmid systems would be equally beneficial in the context of gene or protein delivery using bacteria, 19, 20 since such a system is required for plasmid maintenance within the vector. In that case, a particular attention should be paid to the choice of the selection strategy and any modification of the bacterial vector should be carefully considered. Also, activation of the innate immunity by prokaryotic plasmid backbone must be taken into account. Double stranded prokaryotic DNA is a potent activator of immune system through recognition of unmethylated CpG sequences by the Toll-like receptor 9. 21 Other DNA-recognizing proteins trigger innate immunity, such as the DNA-dependent activator of interferon-regulatory factors. 22 If innate immunity activation might represent a potential adjuvant advantage for DNA-based vaccination, on the other side, it represents an unwanted negative effect for gene therapy strategies implying a sustained, long-lasting expression of the therapeutic transgene. In this latter case, plasmids devoid of prokaryotic antibiotic resistance gene and bearing a shorter prokaryotic backbone may display a decisive advantage.
new SelectIon MArkerS For PlASMId ProductIon complementation of auxotrophic bacterial strains
Auxotrophy is defined as the inability of an organism to synthesize a particular organic compound required for its growth. To produce antibiotic-free plasmid by using this strategy, the bacterial strain is first modified by introducing a deletion or a nonsense point mutation into an essential or conditionally essential chromosomal gene resulting in auxotrophy. Bacterial growth is restored upon introduction into those strains of a plasmid either carrying the deleted gene or coding a suppressor tRNA which allows a complete translation of the truncated protein (Figure 1) . Several target genes have been studied in the last few years and the developed strategies showed promising results ( Table 1) .
Glycine auxotrophy was obtained after chromosomal disruption of the glyA gene that encodes serine hydroxymethyl transferase which is involved in the main glycine biosynthesis pathway in Escherichia coli E. coli. 23 The resulting mutant strain can grow fast only if glycine is added to the culture medium. A complementation plasmid with a functional copy of the glyA gene was constructed providing a serine hydroxymethyl transferase source and thus allowing growth of the auxotrophic bacterial strain. Plasmid constructs based on this backbone could therefore be selected and maintained in culture without addition of antibiotics. The capability of this system for recombinant overproduction of rhamnulose 1-phosphate aldolase was evaluated, obtaining high cell density cultures and productivity levels comparable to those obtained with a conventional system. 23 QAPRTase, an enzyme implied in de novo nicotinamide adenine dinucleotide biosynthesis, appeared recently as another attractive target for auxotrophy-based system. 24 The fact that the QAPRTase gene is ubiquitous in bacteria and mammals addresses a key point in term of biosafety reducing side effects of a potential horizontal gene transfer. Bacteria deficient in QAPRTase are able to survive in common rich media such as lysogeny broth medium (which contains abundant nicotinamide adenine dinucleotide precursors) but under conditions of nutritional deficiency the de novo nicotinamide adenine dinucleotide biosynthesis pathway becomes necessary for bacterial growth. The growth status of the transformed strains was better than that of the prototrophic reference strain as the overproduction of QAPRTase did not lead to metabolic-burden effect. Similarly, translation initiation factor 1 auxotrophic strain was developed by chromosomal deletion of the infA gene. 25 The main advantage of infA targeting is that this protein is made of only 71 amino acids, and plasmids carrying this selectable marker can therefore be maintained small. Growth rates of the control and the plasmid-harbouring strains are indistinguishable from each other.
Two other groups studied an alternative way to get and bypass auxotrophy. Auxotrophic strains were obtained by introducing an amber nonsense mutation into the target gene. The plasmids contained an amber suppressor tRNA (around 100 bp) which inserts an amino acid in response to UAG thus allowing a complete translation of the truncated protein. The first plasmid developed, called pCOR, 26, 27 aimed to overcome an arginine auxotrophy. Interestingly, it also contains a conditional origin of replication that requires the trans-acting π initiator protein encoded by the pir gene integrated into the E. coli host chromosome for its propagation, thus limiting the risk of plasmid dissemination to other bacterial strains. High yields of supercoiled pCOR were obtained by high cell-density fermentation with a yield of 100 mg/l. Furthermore, a particular combination of mutations of the π initiator protein has lead to a threefold-to fivefold increase in supercoiled monomer pCOR plasmid per biomass unit. 27 In another approach, a thymidine auxotrophic strain was isolated for the production of pFAR plasmids. This antibiotic-free system offers the possibility of using a commercially available thymidine-free medium. At similar optical density or after overnight growth, the amount of purified pFAR plasmids was equivalent to that of a pVAX2 derivative prepared from DH5α grown in lysogenic broth medium supplemented with kanamycin. 28 The small size pFAR plasmid led to high transgene expression in several tissues.
toxin-antitoxin-based systems
Toxin-antitoxin systems are made of two key elements: a biologically active protein molecule and the corresponding inhibitor. Such mechanisms have been developed by bacteria as metabolism regulators ensuring an adequate response to environmental changes. 29 Some well-described toxin-antitoxin systems, also called postsegregational killing systems, have emerged as alternatives to the use of antibiotic for plasmid selection.
Killer loci were inserted into the plasmid as selection marker. The selection is based on the fact that toxin and antitoxin elements have different half-life times, the poison protein being more stable. After the loss of the plasmid, expression of both of them stops but the toxin remains in the cell for a longer period of time and thus induces the killing of the bacteria (Figure 2) . This method presents several advantages: (i) no changes must be made on the host's chromosome although chromosomal integration of the "poison" protein might confer some advantage (such as in the following example), (ii) killer loci are generally small, and (iii) media or reactor configuration changes do not impact the selection efficiency. 30 The small CcdB protein is an inhibitor of the essential gyrase and is toxic for enterobacteriaceae as E. coli 31 but not for eukaryotic cells. In the same operon, the ccdA gene encodes the antidote which interacts with the toxin and the resulting complex strongly represses the ccd promoter. Separation of the components of this ccd operon has led to a more efficient system for bacterial selection. 32 The ccdB poison gene was integrated into the bacteria chromosome downstream to the ccd promoter, and the ccdA gene was inserted into an expression plasmid. In case of the absence or loss of the plasmid, the toxin is produced and induces cell death (Figure 2) . The separation of both components ensured efficient killing of plasmid-free cells but also an increase of plasmid-containing bacteria and of plasmid production. The same approach was used to produce proteins as vaccines or therapeutical proteins. It was shown that this method enables to reach higher yields of protein of interest compared to standard method based on antibiotic resistance selection. 33 However, as for the auxotrophy complementation approaches, this strategy requires modification of the host bacterial genome.
operator-repressor titration
Operator-repressor systems can be used to reversibly control the expression of a gene. Several studies aimed at introducing such regulatory sequences upstream from a specific gene in the chromosome of E. coli. Plasmids containing one or several operator sequences were engineered and, when introduced into bacteria, were able to competitively titrate the repressor allowing thus expression of the gene (Figure 3) .
To demonstrate applicability of this system, the Kan r gene was placed under the control of the lac operator/promoter and inserted into the bacterial chromosome. The resulting strain was unable to grow in the presence of kanamycin because of repression of the kanamycin resistance gene, but after transformation with a high copy number plasmid (it was critical that the plasmid copy number per cell was sufficient to achieve repressor titration) containing the lac operator, kan expression was derepressed thus allowing selection. 34 This selection method was adapted to obtain a totally antibiotic-free procedure. A lac operator/promoter was inserted upstream of the essential chromosomal dapD gene, and a new pORT plasmid able to titrate the repressor was constructed. 35 The DapD protein is involved in the lysine/diaminopimelate pathway, and the dapD repression is lethal when bacteria are grown in lysine/diaminopimelate-free media. The pORT vector titrates the repressor, thus allowing the selection of plasmid-containing bacteria. As in the case of other methods described above, it is necessary to modify the chromosomal genome.
rnA-based selection markers
Other selection markers are based on antisense RNA regulators. An RNA IN-sacB sequence was chromosomally integrated and constitutively expressed acting as a selection marker since cells containing sacB encoding levansucrase are killed in the presence of sucrose 36 (Figure 4) . A rescuing plasmid expressing a 150-bp RNA-OUT antisense RNA was constructed. The antisense RNA-OUT hybridized with the RNA-IN sequence and silenced sacB expression thus allowing growth in sucrose-complemented media. Replacement of kanamycin resistance marker with RNA-OUT was not detrimental to plasmid production yield and quality. 36 This vector was recently improved by incorporation of transient expression enhancers which appeared more potent alternatives to improve transgene expression for gene therapy or vaccination. 37 A similar approach was developed using the origin of replication (ori)-encoded RNAI which is common in ColE1-based plasmids (Figure 4) . Similarly to the operator-repressor titration strategy, an essential gene of E. coli was placed under the control of an operator-repressor system but, in that case, the repressor was fused to an RNAII sequence. When plasmids are present in the cells, RNAI derived from the origin of replication hybridizes to the RNAII sequence, inhibiting the repressor translation. 38 Using this strategy, a twofold increase in the overall plasmid yield was obtained compared to the conventional approach using a kanamycin marker gene probably because of a combination of several effects: a decrease in metabolic load, a decrease in the plasmid size, and an increase in replication rate. The main advantage of this approach is that it does not require additional sequence on the plasmid backbone because the selection marker is part of the replication origin. 
overexpression of a growth essential gene
It has been shown that overexpression of certain growth essential genes (fabI or murA) in E. coli reduced their susceptibility to antimicrobial compounds. 39 The fabI gene encodes an enoyl ACP reductase that catalyzes fatty acid elongation. Its overexpression resulted in reduced susceptibility to triclosan, an antibacterial agent acting as a chemical inhibitor of enoyl ACP reductase. This characteristic allowed the development of a new cloning vector pFab 40 which codes for fabI (860 bp). If fabI overexpression and triclosan were toxic when used alone, their combination resulted in enhanced growth of bacteria and in plasmid production ( Figure 5 ). An advantage over the other antibiotic-free systems is that this approach does not require mutant host strain and is thus easier to develop. On the other side, triclosan has to be present in the bacterial cell culture and has to be carefully eliminated from purified plasmid DNA. Moreover, this method requires gene overexpression which could represent a burden of energy.
MInIcIrcleS
In the minicircle strategy, an antibiotic resistance gene is first included into the constructs as a selection marker and then eliminated by site-specific recombination in E. coli (for review, 41, 42 ). Minicircles were first obtained by att site-specific recombination mediated by the phage λ integrase. 16, 43, 44 Another approach consisted in the Cre-mediated and Cre-directed excision of the bacterial vector sequences to create minicircles. 45 After purification, the resulting Manganese superoxide dismutase Protection of mice from irradiation -68
Hypoxia-inducible factor-1 α Improvement of transfection efficiency, duration of transgene expression and cardiac contractility -63 minicircles are small supercoiled DNA molecules containing almost exclusively the gene of interest and its regulating sequence motifs and are devoid of antibiotic resistance gene. Previously, purification was obtained by two time-consuming and labour-intensive steps: the bacterial DNA backbone was digested by a restriction enzyme, and the miniplasmid was then purified by ultracentrifugation on cesium chloride. Two strategies have been developed to facilitate minicircle purification. Inclusion of the endonuclease I-SceI together with its recognition site in the plasmid backbone allowed linearization and degradation of the backbone and production of purified minicircles. 46, 47 Beside, a new affinity-based chromatographic purification approach allowed isolation of highly pure minicircles. 48 If antibiotic are still required for minicircle production, the removing of the antibiotic resistance gene combined with a careful elimination of antibiotic residues in the product make this approach highly promising as it offers small, CpG-free, supercoiled products suitable for gene therapy treatments.
rePorted uSeS oF AntIbIotIc-Free PlASMIdS For Gene tHerAPy
Till now, only some studies have reported the use of antibioticfree plasmids in preclinical and clinical models. This is probably mainly because of the fact that most of these approaches are relatively recent and that the kanamycin selection marker remains allowed for gene therapy clinical trials. [5] [6] [7] [8] However, several studies have been performed using antibiotic-free plasmids with the objective of increasing biosafety ( Table 2) .
All studies that aimed at comparing the efficiency of these plasmids with common vectors containing antibiotic resistance gene reported equal or higher efficacy of the antibiotic-free plasmids in term of luciferase expression. 26, 28 The pCOR plasmid developed at the end of the nineties has been used in several preclinical models such as arthritis, 49, 50 neuropathy, 51 β-thalassemia, 52 and ischemia, 53, 54 and no vector-related toxicity has been reported. The promising results obtained in rabbit and hamster after intramuscular injection of pCOR encoding fibroblast growth factor 1 led to human phase 1 and 2 clinical studies which have suggested an improvement of perfusion and an increase in amputationfree survival in patients with critical limb ischemia. 55, 56 The more recent pFAR plasmid was compared to a vector containing Kan r and equal or higher expression of luciferase was obtained with the pFAR when electrotransfered into muscle, skin, or tumor. 28 The pORT vector was chosen to develop a HIV-1 DNA vaccine, and its delivery induced a specific immune response in both animals and patients. [57] [58] [59] The pORT plasmid encoding an artificial HPV-16 E7-gene was also able to generate an immune response after intramuscular injection into mice. 60 Finally, the same vector expressing Leishmania infantum LACK antigen was shown protective in a canine experimental model. 61 The pORT plasmid AMEP coding for the recombinant disintegrin domain of ADAM 15 62 is presently being evaluated in a phase 1 clinical trial to treat advanced or metastatic melanoma by using electrotransfer (BioAlliance Pharma, personal communication, 20 November 2010). The Staby system based on the use of toxin-antitoxin system was tested in preclinical trials and compared to a conventional Kan R plasmid. It was shown that equal or higher expression and immunogenicity are obtained in mice using the antibiotic-free plasmid (Delphi Genetics, personal communication, 30 May 2011). Minicircles have been used in several preclinical mice models and have demonstrated equal or higher expression in heart, 63, 64 liver, 65 tumor, 66 or muscle 64, 67 and are therefore another attractive alternative for gene therapy of various diseases.
It is important to underline that toxicity or vector-related side effects have never been reported and that, when compared to classical plasmids, antibiotic-free systems revealed equivalent or even higher efficiency. These first data ranked therefore antibiotic-free plasmids among the very promising vectors for future gene therapy clinical trials.
dIScuSSIon And Future dIrectIonS
During the last decades, gene therapy has known a growing interest and has met many preclinical successes both for treatment and prevention of a wide variety of diseases. Today, it is critical to be aware of the potential safety concerns of the gene therapy approaches and to offer therapies that meet the highest expectations of effectiveness and safety. The use of antibiotic resistance genes as selection markers raises concerns which are regularly pointed out by the authorities. [5] [6] [7] [8] We can reasonably anticipate that, in the next few years, antibiotic resistance genes as selection markers will become more restricted or even forbidden for a clinical use because of the risk of horizontal gene transfer and because of the allergic potential of the compounds used for plasmid maintenance. In this paper, we reviewed the new generation of plasmid backbones devoid of antibiotic resistance marker which has recently emerged. An ideal selection marker should have all the following properties: (i) if a horizontal gene transfer occurs, it should not impact the recipient cell. In particular, the plasmid should not provide the bacteria with any benefit as it is the case for antibiotic resistance genes. (ii) The selection marker should have a limited impact on the plasmid size and should not induce immune activation. (iii) The marker cannot be toxic for eukaryotic cells. (iv) Plasmid maintenance should not require the presence of potentially harmful compounds or very sensitive detection methods should be applied to guarantee their complete removal.
(v) Plasmid yields should be high even in large culture, and the culture media required should be easily available and inexpensive to allow scaling-up. As available data about purity and yields using the different approaches is very heterogeneous, it would be interesting to perform a systematic comparative study.
Several of the strategies described in this review meet many of the required characteristics, and when more preclinical and clinical data will be provided proving both efficiency and safety, these vectors will certainly play a major role in the development of the future gene therapies.
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